VRDN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VRDN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Viridian Therapeutics's share price for the quarter that ended in Dec. 2024 was $19.17. Viridian Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2024 was 80.99 Mil. Therefore, Viridian Therapeutics's market cap for the quarter that ended in Dec. 2024 was $1,552.65 Mil.
Viridian Therapeutics's quarterly market cap increased from Jun. 2024 ($831.08 Mil) to Sep. 2024 ($1,801.37 Mil) but then declined from Sep. 2024 ($1,801.37 Mil) to Dec. 2024 ($1,552.65 Mil).
Viridian Therapeutics's annual market cap declined from Dec. 2022 ($1,206.55 Mil) to Dec. 2023 ($1,175.82 Mil) but then increased from Dec. 2023 ($1,175.82 Mil) to Dec. 2024 ($1,552.65 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Viridian Therapeutics's Enterprise Value for Today is $789.64 Mil.
The historical data trend for Viridian Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
69.60 | 472.98 | 1,206.55 | 1,175.82 | 1,552.65 |
Viridian Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Market Cap | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1,175.82 | 1,117.12 | 831.08 | 1,801.37 | 1,552.65 |
For the Biotechnology subindustry, Viridian Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Viridian Therapeutics's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
Market Cap (A: Dec. 2024 ) | = | Share Price (A: Dec. 2024 ) | * | Shares Outstanding (EOP) (A: Dec. 2024 ) |
= | $19.17 | * | 80.994 | |
= | $1,552.65 |
Viridian Therapeutics's Market Cap for the quarter that ended in Dec. 2024 is calculated as
Market Cap (Q: Dec. 2024 ) | = | Share Price (Q: Dec. 2024 ) | * | Shares Outstanding (EOP) (Q: Dec. 2024 ) |
= | $19.17 | * | 80.994 | |
= | $1,552.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (NAS:VRDN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Viridian Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas W. Beetham | officer: Chief Operating Officer | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Stephen F. Mahoney | director, officer: President and CEO | C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11 |
Fairmount Healthcare Fund Ii Gp Llc | director, other: See Remarks | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Fairmount Healthcare Fund Gp Llc | director, other: See Remarks | 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103 |
Sarah Gheuens | director | C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139 |
Seth Harmon | officer: See Remarks | C/O VIRIDIAN THERAPEUTICS, INC., 221 CRESCENT STREET, SUITE 401, WALTHAM MA 02453 |
Lara Meisner | officer: General Counsel and Secretary | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG. 17, SUITE 102, WALTHAM MA 02453 |
Scott Dunseth Myers | director, officer: Chief Executive Officer | C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121 |
Jonathan Violin | officer: President and COO | 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087 |
Barrett Katz | officer: Chief Medical Officer | 6200 LOOKOUT ROAD, C/O MIRAGEN THERAPEUTICS, INC., BOULDER CO 80301 |
Carrie Melvin | officer: COO | C/O VIRIDIAN THERAPEUTICS, INC., 203 CRESCENT STREET, BLDG 17, SUITE 102B, WALTHAM MA 02453 |
Frazier Life Sciences Public Fund, L.p. | 10 percent owner | TWO UNION SQUARE, 601 UNION ST., SUITE 3200, SEATTLE WA 98101 |
Fhmlsp, L.l.c. | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
L.p. Fhmlsp, | 10 percent owner | C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200, SEATTLE WA 98101 |
Kristian Humer | officer: CFO and CBO | C/O VIRIDIAN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER CO 80301 |
From GuruFocus
By GuruFocus News • 10-18-2024
By GuruFocus News • 12-16-2024
By GuruFocus News • 11-15-2024
By Business Wire • 09-09-2024
By GuruFocus Research • 10-01-2024
By GuruFocus News • 01-08-2025
By Business Wire • 06-11-2024
By Business Wire • 11-05-2024
By Business Wire • 02-06-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.